Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials)

By afschroeder • March 25, 2026

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Rickard K, O'Donovan K, Sciurba F. Summary of Research: Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trials (the ENHANCE Trials). Adv Ther. 2026 Mar 24. doi: 10.1007/s12325-026-03514-6. Epub ahead of print. PMID: 41874851.

Tags: COPD, Dual PDE3, ensifentrine, nebulized therapy, PDE4 Inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Preoperative Thrombocytopenia and Risk of Periprosthetic Joint Infection After Total Knee Arthroplasty: A Propensity-Matched Cohort Study

Wiener JM, Hamad CD, Chun RF, Mehany JD, Yeaman MR, Sheppard WL, Bernthal NM. Preoperative Thrombocytopenia and Risk of Periprosthetic Joint Infection After Total Knee[...]

Impact of posttraumatic stress disorder on incident cardiovascular outcomes in women veterans: a retrospective longitudinal study

Ebrahimi R, Dennis PA, Alvarez CA, Shroyer AL, Beckham JC, Sumner JA. Impact of posttraumatic stress disorder on incident cardiovascular outcomes in women veterans: a[...]

Pulmonary Alveolar Proteinosis: Rethinking Surfactant Homeostasis Through Alveolar Macrophage Lipid-Handling Dysfunction

Lee E, Little IJ, Dantas L, Tarling EJ. Pulmonary Alveolar Proteinosis: Rethinking Surfactant Homeostasis Through Alveolar Macrophage Lipid-Handling Dysfunction. Arterioscler Thromb Vasc Biol. 2026 Sep[...]